Contents of Volume 12

N	10	4

E. De Clercq (Belgium)	
New acquisitions in the development of anti-HIV agents (Review Article)	1
N. Yamamoto, H. Furukaza, Y. Ito, S. Yoshida, K. Maeno and Y. Nishiyama (Japan)	
Anti-herpesvirus activity of citrusinine-I, a new acridone alkaloid, and related compounds	21
M.J. Tymms, B. McInnes, G.J. Waine, B.F. Cheetham and Linnane (Australia)	
Functional significance of amino acid residues within conserved hyrophilic regions in hu-	
man interferons- α	3
P.G. Higgins, G.I. Barrow, A.W. Galbraith, H. Frost and D.A.J. Tyrrell (U.K., Switzerland)	
A note on the failure of CGP 19835 A (MTP-PE) to influence the course of influenza A2	
infection in human volunteers (Short Communication)	4
Announcements	5
No. 2	
J.B. Hudson (Canada)	_
Plant photosensitizers with antiviral properties (Review Article)	5
R.A. Heijtink, G.A. de Wilde, J. Kruining, M.B.L. Smit-Leijs and S.W. Schalm (The Neth-	
erlands)	
Anti-pre-s(2) analysis after hepatitis B vaccination in haemodialysis patients	7
M. Hosoya, S. Shigeta, K. Nakamura and E. De Clercq (Japan, Belgium)	
Inhibitory effect of selected antiviral compounds on measles (SSPE) virus replication in	
vitro	8
G. Spedding, A. Ratty and E. Middleton, Jr. (U.S.A.)	
Inhibition of reverse transciptases by flavonoids	9
Announcements	11
No. 3	
J.A. Montgomery (U.S.A.)	
Approaches to antiviral chemotherapy (Mini Review)	11
A. Van Aerschot, P. Herdewijn, G. Janssen, M. Cools and E. De Clercq (Belgium)	
Synthesis and antiviral activity evaluation of 3'-fluoro-3'-deoxyribonucleosides: broad-	
spectrum antiviral activity of 3'-fluoro-deoxyadenosine	13

K. Kiyosawa, T. Sodeyama, Y. Nakano, H. Yoda, E. Tanaka, T. Hayata, K. Tsuchiya, M. Yousuf and S. Furuta (Japan)	
Treatment of chronic non-A non B hepatitis with human interferon B: a preliminary study	151
Announcement	163
No. 4	
H.J. Field and G.A. Brown (U.K.) Animal models for antiviral therapy (Mini-Review)	165
M.J.C. Aquino-de Jesus and B.P. Griffith (U.S.A.) Cytomegalovirus infection in immunocompromised guinea pigs: a model for testing an-	
tiviral agents in vivo	181
L. Borecký, P. Kontsek, M. Novák and V. Lackovič (Czechoslovakia)	
Human acid- and thermolabile α-interferon-like substance: selective reactivity with a	195
monoclonal antibody	195
V.R. Freitas, E.B. Fraser-Smith and T.R. Matthews (U.S.A.)	
Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus	
and herpes simplex virus type 2 in vitro an in vivo	205
S-S. Choi, R. Rasshofer and M. Roggendorf (F.R.G.)	
Inhibition of hepatitis delta virus RNA replication in primary woodchuck hepatocytes (Short	
Communication)	213
No. 5, 6	
R.O. Spertzel (U.S.A.)	
Animal models of human immunodeficiency virus infection (Mini-Review)	223
S.J. Sperber and F.G. Hayden (U.S.A.)	
Protective effect of rhinovirus receptor blocking antibody in human fibroblast cells	231
G.D. Hsiung and V.F. Chan (U.S.A.)	
Evaluation of new antiviral agents: II. The use of animal models	239
L.B. Allen, A.G. Teepe, M.J. Kehoe, C.S. Holland, D.J. McNamara and P.D. Cook (U.S.A.)	
Antiviral and cytotoxicity evaluation of 3-nitro-3-deazauridine	259
PZ. Tao. N.G. Johansson, G. Stening, B. Öberg and F. Datema (P.R. China, Sweden)	
Inhibition of HIV-1 reverse transcriptase by 5'-triphosphates of 5-substituted uridine an-	
alogs	269
H.L. Lucia, D.H. Coppenhaver and S. Baron (U.S.A.)	
Arenavirus infection in the guinea pig model: antiviral therapy with recombinant inter-	
feron-α, the immunomodulator CL246, 738 and ribavirin	279

323